https://doi.org/10.4081/reumatismo.2024.1686
Patients with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis resembling antisynthetase syndrome with poor prognosis: a bicentric international retrospective study and literature review
Submitted: 28 November 2023
Accepted: 9 June 2024
Published: 9 October 2024
Accepted: 9 June 2024
Abstract Views: 326
PDF: 78
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Objective. This study aimed to describe adult Brazilian and Japanese patients with anti-small ubiquitin-like modifier activating enzyme (SEA)-positive dermatomyositis (DM), as there are few studies in the literature. A literature review was also conducted.
Methods. This bicentric international retrospective study, conducted between 2012 and 2023, included patients with anti-SAE-positive DM (2017 European League Against Rheumatism/American College of Rheumatology classification criteria). All demographic features and clinical, laboratory, therapeutic, and follow-up data were collected from Brazilian and Japanese centers using pre-standardized and parameterized information.
Results. We included 17 adult patients with a median age of 65 (56-76) and a predominance of females (82.4%). Constitutional symptoms at baseline were present in 58.8% of the patients. In addition to classical cutaneous DM lesions, one-third of the patients had myalgia and significant muscle weakness, whereas half presented with dysphagia, interstitial lung disease, and joint manifestations. The first-line treatment consisted of intravenous methylprednisolone and immunoglobulin pulse therapy in 41.2% and 28.6% of the patients, respectively. The median follow-up duration was 20 (13-74) months; at the last medical evaluation, half had active disease and were still using oral glucocorticoids (median dosage, 10.0 mg/day). Approximately one-fifth to one-third of the patients were diagnosed with different types of cancer, had severe infections, or died.
Conclusions. Patients with anti-SAE-positive DM not only resemble the phenotype of antisynthetase syndrome but are also associated with a poor prognosis.
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76: 1955-64.
DOI: https://doi.org/10.1136/annrheumdis-2017-212786
Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity, and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; 101: 48-55.
DOI: https://doi.org/10.1016/j.jaut.2019.04.001
Demortier J, Vautier M, Chosidow O, Gallay L, Bessis D, Berne A, et al. Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology 2023; 62: 3932-9.
DOI: https://doi.org/10.1093/rheumatology/kead154
Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllõsi L, Dankó K. Four dermatomyositis-specific autoantibodies - anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014; 13: 1211-9.
DOI: https://doi.org/10.1016/j.autrev.2014.08.011
Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 2013; 46: 279-84.
DOI: https://doi.org/10.3109/08916934.2012.755958
Albayda J, Mecoli C, Casciola-Rosen L, Danoff SK, Lin CT, Hines D, et al. A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases. ACR Open Rheumatol 2021; 3: 287-94.
DOI: https://doi.org/10.1002/acr2.11247
Ge Y, Lu X, Shu X, Peng Q, Wang G. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep 2017; 7: 188.
DOI: https://doi.org/10.1038/s41598-017-00240-6
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132-7.
DOI: https://doi.org/10.1002/art.22862
Truzzi NCC, Hoff LS, Borges IBP, De Souza FHC, Shinjo SK. Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study. Adv Rheumatol 2022; 62: 41.
DOI: https://doi.org/10.1186/s42358-022-00276-x
Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 2012; 384: 128-34.
DOI: https://doi.org/10.1016/j.jim.2012.07.019
Jia E, Wei J, Geng H, Qiu X, Xie J, Xiao Y, et al. Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review. Clin Rheumatol 2019; 38: 2189-93.
DOI: https://doi.org/10.1007/s10067-019-04562-w
De Vries M, Schreurs MWJ, Ahsmann EJM, Spee-Dropkova M, Karim F. A case of anti-SAE1 dermatomyositis. Case Reports Immunol 2022; 2022: 9000608.
DOI: https://doi.org/10.1155/2022/9000608
Kishi T, Tani Y, Okiyama N, Mizuochi K, Ichimura Y, Harigai M, et al. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report. Pediatr Rheumatol 2021; 19: 34.
DOI: https://doi.org/10.1186/s12969-021-00532-2
Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 2013; 72: 151-3.
DOI: https://doi.org/10.1136/annrheumdis-2012-201736
Gono T, Tanino Y, Nishikawa A, Kawamata T, Hirai K, Okazaki Y, et al. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: a potential unique subset of dermatomyositis-associated interstitial lung disease. Int J Rheum Dis 2019; 22: 1582-6.
DOI: https://doi.org/10.1111/1756-185X.13593
Peterson LK, Jaskowski TD, La’ulu SL, Tebo AE. Antibodies to small ubiquitin-like modifier activating enzymes are associated with a diagnosis of dermatomyositis: results from an unselected cohort. Immunol Res 2018; 66: 431-6.
DOI: https://doi.org/10.1007/s12026-018-9006-7
Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WER, Cooper RG, et al. Clinical and human leukocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009; 68: 1621-5.
DOI: https://doi.org/10.1136/ard.2008.097162
Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 2607-15.
DOI: https://doi.org/10.1002/art.21291
Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. J Am Acad Dermatol 2003; 48: 797-8.
DOI: https://doi.org/10.1067/mjd.2003.199
Cruellas MGP, Viana VST, Levy-Neto M, De Souza FHC, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 2013; 68: 909-14.
DOI: https://doi.org/10.6061/clinics/2013(07)04
How to Cite
de Carvalho, C., Bayeh, B., de Souza, F., Miossi, R., Inaoka, P., Matsushita, T., … Shinjo, S. (2024). Patients with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis resembling antisynthetase syndrome with poor prognosis: a bicentric international retrospective study and literature review. Reumatismo. https://doi.org/10.4081/reumatismo.2024.1686
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- J. Mencarini, M. Spinicci, F. Bartalesi, Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter? , Reumatismo: Vol. 68 No. 3 (2016)
- S. Canestri, M.C. Totaro, E. Serone, B. Tolusso, D. Frezza, E. Gremese, G. Ferraccioli, Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients , Reumatismo: Vol. 64 No. 6 (2012)
- F.M. Perrotta, E. Lubrano, New approved drugs for psoriatic arthritis , Reumatismo: Vol. 68 No. 2 (2016)
- C.-N. Lo, G. Xia, B.P. Leung, The effect of nerve mobilization exercise in patients with rheumatoid arthritis: a pilot study , Reumatismo: Vol. 69 No. 3 (2017)
- F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro, Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs , Reumatismo: Vol. 66 No. 3 (2014)
- A. Ghirardello, S. Zampieri, L. Iaccarino, E. Tarricone, M. Tonello, R. Bendo, R. Rondinone, F. Cozzi, A. Doria, Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients , Reumatismo: Vol. 57 No. 1 (2005)
- F.H.C. De Souza, D.B. De Araújo, L.S. Hoff, B.G. Baldi, M.S.M.S. Faria, L.F da Rocha Junior, L.R.S Da Silva, G.L Behrens Pinto, M.C. Bezerra, R. Miossi, R.A. Cordeiro, S.K Shinjo, Diagnosis and treatment of interstitial lung disease related to systemic autoimmune myopathies: a narrative review , Reumatismo: Vol. 75 No. 1 (2023)
- D. Fornasari, S. Coaccioli, Pharmacology of pain , Reumatismo: Vol. 66 No. 1 (2014)
- A. Alunno, V. Caneparo, F. Carubbi, O. Bistoni, S. Caterbi, M. Gariglio, E. Bartoloni, S. Landolfo, R. Gerli, Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren’s syndrome: findings in serum and minor salivary glands , Reumatismo: Vol. 67 No. 3 (2015)
- F. Atzeni, L. Boccassini, M. Di Franco, A. Alciati, A. Marsico, M. Cazzola, G. Cassisi, P. Sarzi-Puttini, Chronic widespread pain in spondyloarthritis , Reumatismo: Vol. 66 No. 1 (2014)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
